We always look at Alphabet as less search engine, and more about new tactical insights and tech that comes to the top and is transformative.” “When GV was founded in 2009, some people were surprised to see us involved in therapeutics-externally, it can be a little confusing. “At a high level, GV is set up as a fund where Alphabet is given a mandate to invest profitably,” Yeshwant explains. Speaking by phone, GV general partner Krishna Yeshwant credits his firm’s involvement in biopharma and life sciences to a rise in potentially transformative products both on the market and in development. GV is part of a wave of tech-centric VC firms like Andreessen Horowitz, Kleiner Perkins Caufield & Byers, and Venrock Associates that are joining the party. Venture capital for biopharma has traditionally been dominated by pharma company funds such as Pfizer Venture Investments, Amgen Ventures, and GSK’s. The fund’s life science and health division includes dozens of other firms, including Foundation Medicine, Cambridge Epigenetix, Metabiota, and Oscar.įor Alphabet and Google, pharmaceuticals and biology occupy the convergence of two intersecting trends-a rise in massive data sets used to develop drugs and treatments, and the ability to turn a profit by backing potentially world-changing technologies in their early stages. The venture capital arm of Google holding company Alphabet has investments in many of biopharma’s best known names, including Editas, 23andMe, Grail, and Denali Therapeutics. GV, formerly and popularly known as Google Ventures, has been making a major push into biopharma and life sciences. Get a free trial today and find answers on the fly, or master something new and useful. Join the O'Reilly online learning platform.
0 kommentar(er)
